Objective To compare the therapeutic effects and toxic reactions of DP regimen (docetaxel plus cisplatin) and GP regimen (gemcitabine plus cisplatin) in the treatment of advanced stage non-small cell lung career (NSCLC). Methods A total of 79 patients with advanced stage NSCLC were treated by first-line chemotherapy for 4~6 weeks. The patients were divided into two groups: DP group (docetaxel plus cisplatin) and GP group (gemcitabine plus cisplatin). Patients in DP group (n=43) were treated by 75 mg/m2 docetaxel on day 1 plus 25 mg/m2 cisplatin on day I to day 3. Patients in GP group (n=36) were treated by 1000 mg/m2 gemcitabine on day 1 and day 8 plus 25 mg/m2 cisphtin on day 1 to day 3. Twenty-one days were a treatment cycle. The treatment response rate and survival rate were evaluated by the end of every two cycles. Results The response rate was 37.21% for DP group and 33.33% for GP group, with no statistically significant difference between the two groups (P>0.05). The response rate also had no statistically significant difference in adenocarcinoma and squamous carcinoma sub-groups. The main side effects were myelosup-pression, nausea and omiting. There was no statistically significant difference in Ⅲ ~Ⅳ grade thrombocytopenia and gastrointestinal side effects between the two groups. Conclusion Both DP regimen (docetaxel and cisplatin) and GP regimen (gemcitabine and cisplatin) in first-line chemotherapy have good therapeutic effects and toleranted toxic reactions in the treatment of advanced stage non-small cell lung cancer (NSCLC).%目的 比较多西他赛联合顺铂与吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的疗效和不良反应.方法 晚期非小细胞肺癌患者79例,均接受4～6周期一线化疗.多西他赛联合顺铂组(DP组)43例:多西他赛75 mg/m2,第1天,顺铂25 mg/m2,第1～3天.吉西他滨联合顺铂组(GP组)36例:吉西他滨1 000 mg/m2,第1天、第8天,顺铂用量同DP组.21d为一个化疗周期,每2周期评估化疗疗效并随访生存期.结果 DP组有效率为37.21％,GP组有效率为33.33％,两组有效率差异无统计学意义(P＞0.05).腺癌、鳞癌亚组有效率差异无统计学意义.两组主要毒副反应为骨髓毒性和胃肠道反应,Ⅲ～Ⅳ度的血小板下降和胃肠道反应差异无统计学意义.结论 多西他赛和吉西他滨分别联合顺铂一线治疗晚期非小细胞肺癌疗效高,毒副反应可以耐受.
展开▼
